Utilization of Cancer Navigators in the Management of Gastric Cancer: A Systematic Review.

J Surg ResJul 3, 2026 (epub)
Clinical ResearchOncology (Medical)Gastroenterology

Natalie N Martinez, Kyle D Klingbeil, Vanessa M Molina et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the role of cancer navigation programs in managing gastric cancer, analyzing seven studies with 3465 patients. While navigation programs showed improvements in quality of life, nutritional status, and patient satisfaction, they did not consistently enhance survival or treatment adherence. The review highlights the need for standardized studies to better understand these interventions.

Key findings

  • Navigation programs improved quality of life and nutritional status in select studies.
  • No consistent benefits were observed for survival or treatment adherence.
  • The review included seven studies, comprising five observational and two randomized controlled studies.
  • Most interventions were nurse-led and varied widely in structure and outcome assessment.

Why it matters

Understanding the impact of cancer navigation programs on patient outcomes is crucial for optimizing care in gastric cancer. Improved quality of life and patient satisfaction can enhance overall treatment experiences, even if survival benefits are not consistently demonstrated.

Source

PubMed · PMID 42398219

Published in J Surg Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.